123
Participants
Start Date
January 19, 2021
Primary Completion Date
March 26, 2025
Study Completion Date
August 18, 2025
Ravulizumab
Dosages (loading and maintenance) will be based on the participant's body weight.
Placebo
Dosages (loading and maintenance) will be based on the participant's body weight.
Background Therapy
Participants will receive background therapy consistent with the standard of care.
Research Site, Westmead
Research Site, Parkville
Research Site, Herston
Research Site, Seoul
Research Site, New York
Research Site, Berlin
Research Site, Torino
Research Site, Seongnam-si
Research Site, Anyang-si
Research Site, Lübeck
Research Site, New Taipei City
Research Site, Brescia
Research Site, Lleida
Research Site, Chapel Hill
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Málaga
Research Site, Lawrenceville
Research Site, Hanover
Research Site, Toulouse
Research Site, Orlando
Research Site, Plantation
Research Site, Bologna
Research Site, Louisville
Research Site, Taichung
Research Site, Lexington
Research Site, Seville
Research Site, Saint-Priest-en-Jarez
Research Site, Columbus
Research Site, Essen
Research Site, Valencia
Research Site, Zaragoza
Research Site, Florence
Research Site, Clermont-Ferrand
Research Site, Kansas City
Research Site, Strasbourg
Research Site, Paris
Research Site, Houston
Research Site, El Paso
Research Site, Kaohsiung City
Research Site, South Gate
Research Site, Santa Monica
Research Site, San Dimas
Research Site, Le Kremlin-Bicêtre
Research Site, Stanford
Research Site, Kaohsiung City
Research Site, Boston
Research Site, Boston
Research Site, London
Research Site, Montreal
Research Site, Québec
Research Site, Maastricht
Research Site, Lodz
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Barcelona
Research Site, Palma de Mallorca
Research Site, Edgbaston
Research Site, London
Research Site, London
Research Site, Salford
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY